Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.54 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9807649 | 0.84 | NCEH1 (0.51) | NCEH1WDR5KMT2ALDHAKDM4E | |
| SCHEMBL23809161 | 0.84 | WDR5 (0.59) | NCEH1WDR5LDHAKDM4EALDH1A1 | |
| SCHEMBL19695770 | 0.83 | NCEH1 (0.50) | NCEH1WDR5KMT2ALDHAKDM4E | |
| SCHEMBL2882576 | 0.79 | IRAK4 (0.44) | IRAK4KMT2AATMKDM4EPOLB | |
| SCHEMBL12355057 | 0.79 | NCEH1 (0.47) | NCEH1WDR5KMT2ALDHAKDM4E | |
| SCHEMBL3454172 | 0.79 | LCK (0.45) | NCEH1IRAK4KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL9633489 | 0.79 | KMT2A (0.40) | NCEH1WDR5KMT2AATMLDHA | |
| SCHEMBL8609970 | 0.77 | NCEH1 (0.44) | NCEH1WDR5KMT2ALDHAKDM4E | |
| SCHEMBL5153416 | 0.77 | TSHR (0.50) | NCEH1WDR5KMT2AATMLDHA | |
| SCHEMBL6748668 | 0.76 | WDR5 (0.68) | WDR5KMT2AATMLDHAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222174-A1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | claimed |
| WO-2001030762-A1 | IMIDAZOL-4-YLMETHANOLS USE AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-03 | — | — | WO | claimed |
| US-12103902-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| US-20220298102-A1 | BICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-1222174-A1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | Takeda Chemical Industries, Ltd. (JP) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001030762-A1 | IMIDAZOL-4-YLMETHANOLS USE AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298102-A1 | BICYCLIC COMPOUNDS | YAP1, TEAD2, TEAD3 | NCEH1 3528/4885WDR5 2209/4885IRAK4 4021/4885 |
| US-12103902-B2 | Bicyclic compounds | YAP1, TEAD2, TEAD3 | NCEH1 3513/4885WDR5 1789/4885IRAK4 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.